Julia C Gage1, William C Hunt, Mark Schiffman, Hormuzd A Katki, Li A Cheung, Orrin Myers, Jack Cuzick, Nicolas Wentzensen, Walter Kinney, Philip E Castle, Cosette M Wheeler. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health & Human Services, Bethesda, Maryland; the Departments of Pathology, Internal Medicine, and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico; Information Management Services Inc., Calverton, Maryland; the Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, United Kingdom; the Division of Gynecologic Oncology, Kaiser Permanente Medical Care Program, Oakland, California; and the Albert Einstein College of Medicine, New York, New York.
Abstract
OBJECTIVE: To compare the risks of histologic high-grade cervical intraepithelial neoplasia (CIN) or worse after different cervical cancer screening test results between two of the largest U.S. clinical practice research data sets. METHODS: The New Mexico Human Papillomavirus (HPV) Pap Registry is a statewide registry representing a diverse population experiencing varied clinical practice delivery. Kaiser Permanente Northern California is a large integrated health care delivery system practicing routine HPV cotesting since 2003. In this retrospective cohort study, a logistic-Weibull survival model was used to estimate and compare the cumulative 3- and 5-year risks of histologic CIN 3 or worse among women aged 21-64 years screened in 2007-2011 in the New Mexico HPV Pap Registry and 2003-2013 in Kaiser Permanente Northern California. Results were stratified by age and baseline screening result: negative cytology, atypical squamous cells of undetermined significance (ASC-US) (with or without HPV triage), low-grade squamous intraepithelial lesion, and high-grade squamous intraepithelial lesion. RESULTS: There were 453,618 women in the New Mexico HPV Pap Registry and 1,307,528 women at Kaiser Permanente Northern California. The 5-year CIN 3 or worse risks were similar within screening results across populations: cytology negative (0.52% and 0.30%, respectively, P<.001), HPV-negative and ASC-US (0.72% and 0.49%, respectively, P=.5), ASC-US (3.4% and 3.4%, respectively, P=.8), HPV-positive and ASC-US (7.7% and 7.1%, respectively, P=.3), low-grade squamous intraepithelial lesion (6.5% and 5.4%, respectively, P=.009), and high-grade squamous intraepithelial lesion (53.1% and 50.4%, respectively, P=.2). Cervical intraepithelial neoplasia grade 2 or worse risks and 3-year risks had similar trends across populations. Age-stratified analyses showed more variability, especially among women aged younger than 30 years, but patterns of risk stratification were comparable. CONCLUSION: Current U.S. cervical screening and management recommendations are based on comparative risks of histologic high-grade CIN after screening test results. The similar results from these two large cohorts from different real-life clinical practice settings support risk-based management thresholds across U.S. clinical populations and practice settings.
OBJECTIVE: To compare the risks of histologic high-grade cervical intraepithelial neoplasia (CIN) or worse after different cervical cancer screening test results between two of the largest U.S. clinical practice research data sets. METHODS: The New Mexico Human Papillomavirus (HPV) Pap Registry is a statewide registry representing a diverse population experiencing varied clinical practice delivery. Kaiser Permanente Northern California is a large integrated health care delivery system practicing routine HPV cotesting since 2003. In this retrospective cohort study, a logistic-Weibull survival model was used to estimate and compare the cumulative 3- and 5-year risks of histologic CIN 3 or worse among women aged 21-64 years screened in 2007-2011 in the New Mexico HPVPap Registry and 2003-2013 in Kaiser Permanente Northern California. Results were stratified by age and baseline screening result: negative cytology, atypical squamous cells of undetermined significance (ASC-US) (with or without HPV triage), low-grade squamous intraepithelial lesion, and high-grade squamous intraepithelial lesion. RESULTS: There were 453,618 women in the New Mexico HPVPap Registry and 1,307,528 women at Kaiser Permanente Northern California. The 5-year CIN 3 or worse risks were similar within screening results across populations: cytology negative (0.52% and 0.30%, respectively, P<.001), HPV-negative and ASC-US (0.72% and 0.49%, respectively, P=.5), ASC-US (3.4% and 3.4%, respectively, P=.8), HPV-positive and ASC-US (7.7% and 7.1%, respectively, P=.3), low-grade squamous intraepithelial lesion (6.5% and 5.4%, respectively, P=.009), and high-grade squamous intraepithelial lesion (53.1% and 50.4%, respectively, P=.2). Cervical intraepithelial neoplasia grade 2 or worse risks and 3-year risks had similar trends across populations. Age-stratified analyses showed more variability, especially among women aged younger than 30 years, but patterns of risk stratification were comparable. CONCLUSION: Current U.S. cervical screening and management recommendations are based on comparative risks of histologic high-grade CIN after screening test results. The similar results from these two large cohorts from different real-life clinical practice settings support risk-based management thresholds across U.S. clinical populations and practice settings.
Authors: Ming Guo; Abha Khanna; Jianping Wang; Marilyn A Dawlett; Teresa L Kologinczak; Genevieve R Lyons; Roland L Bassett; Nour Sneige; Yun Gong; Therese B Bevers Journal: Cancer Cytopathol Date: 2017-05-12 Impact factor: 5.284
Authors: Carolann Risley; Megan A Clarke; Kim R Geisinger; Mary W Stewart; Lei Zhang; Kim W Hoover; Laree M Hiser; Kenyata Owens; Maria DeMarco; Mark Schiffman; Nicolas Wentzensen Journal: Cancer Cytopathol Date: 2020-04-03 Impact factor: 5.284
Authors: Maria Demarco; Thomas S Lorey; Barbara Fetterman; Li C Cheung; Richard S Guido; Nicolas Wentzensen; Walter K Kinney; Nancy E Poitras; Brian Befano; Philip E Castle; Mark Schiffman Journal: J Low Genit Tract Dis Date: 2017-10 Impact factor: 1.925
Authors: Jesper Bonde; Fabio Bottari; Valentin Parvu; Helle Pedersen; Karen Yanson; Anna D Iacobone; Salma Kodsi; Fabio Landoni; Laurence Vaughan; Ditte M Ejegod; Maria T Sandri Journal: Int J Cancer Date: 2019-04-30 Impact factor: 7.396
Authors: Carolann Risley; Mary W Stewart; Kim R Geisinger; Laree M Hiser; Jody C Morgan; Kenyata J Owens; Krishna Ayyalasomayajula; Rhonda M Rives; Ashish Jannela; Dianne E Grunes; Lei Zhang; Mark Schiffman; Nicolas Wentzensen; Megan A Clarke Journal: Prev Med Date: 2021-07-20 Impact factor: 4.018
Authors: Mark H Stoler; Thomas C Wright; Valentin Parvu; Karen Yanson; Karen Eckert; Salma Kodsi; Charles Cooper Journal: Am J Clin Pathol Date: 2019-03-01 Impact factor: 2.493
Authors: Li C Cheung; Didem Egemen; Xiaojian Chen; Hormuzd A Katki; Maria Demarco; Amy L Wiser; Rebecca B Perkins; Richard S Guido; Nicolas Wentzensen; Mark Schiffman Journal: J Low Genit Tract Dis Date: 2020-04 Impact factor: 3.842